

**WISCONSIN MEDICAID PHARMACY PA ADVISORY COMMITTEE**  
**Recommendations Summary**  
**November 11, 2015**

---

**In Attendance:**

	Committee Member	Yes or No
1	Rosanne Barber	Yes
2	James Boblin M.D.	Yes
3	Ward Brown, M.D.	Yes-Left at 12:45
4	Catherine Decker Pharm.D	Yes
5	Ronald Diamond, M.D.	No
6	John J. W. Fangman, M.D.	Yes
7	Lawrence Fleming M.D.	No
8	Kevin Izard M.D.	Yes-Arrived at 9:30
9	Steve Maike RPh	Yes
10	William E. Raduege, M.D.	Yes
11	Pat Towers	Yes
12	Alicia Walker Pharm.D	No
13	Michael Witkovsky M.D.	No

## NOVEMBER 2015 THERAPEUTIC DRUG CLASS

ANTI-HISTAMINES, MINIMALLY SEDATING  
BRONCHODILATORS, BETA AGONIST  
COPD AGENTS  
GLUCOCORTICOIDS, INHALED  
GLUCOCORTICOIDS, ORAL  
LEUKOTRIENE MODIFIERS  
COUGH AND COLD/NARCOTICS  
EPINEPHRINE, SELF-INJECTED  
INTRANASAL RHINITIS AGENTS  
ANTI-HYPERTENSIVES, SYMPATHOLYTIC  
ANTI-HYPERURICEMICS, ORAL  
BILE SALTS  
ERYTHROPOIESIS STIMULATING PROTEINS  
HISTAMINE 2 RECEPTOR BLOCKERS  
OPHTHALMIC ANTIBIOTIC/STEROID COMBINATIONS  
OPHTHALMIC ANTIBIOTICS  
OPHTHALMIC ANTI-INFLAMMATORIES  
OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS  
OPHTHALMICS, GLAUCOMA AGENTS  
OTIC ANTIBIOTICS  
OTIC ANTI-INFECTIVES  
ANTIPSORIATICS, ORAL  
ANTIPSORIATICS, TOPICAL  
IMMUNOMODULATORS FOR ATOPIC DERMATITIS  
IMMUNOMODULATORS, TOPICAL  
STERIODS, TOPICAL-LOW POTENCY  
STERIODS, TOPICAL-MEDIUM POTENCY  
STERIODS, TOPICAL-HIGH POTENCY  
STERIODS, TOPICAL-VERY HIGH POTENCY  
CYTOKINE AND CAM ANTAGONISTS  
NSAIDS  
NEUROPATHIC PAIN (ANALGESICS/ANESTHETICS TOPICAL AND FIBROMYALGIA)  
ALZHEIMER'S AGENTS  
ANTICONVULSANTS  
ANTIDEPRESSANTS, OTHER  
ANTIDEPRESSANTS, SSRI's  
ANTIPARKINSON'S AGENTS  
ANTIPSYCHOTICS  
ANXIOLYTICS  
SEDATIVE HYPNOTICS  
STIMULANTS AND RELATED AGENTS  
METHOTREXATE-*New Class*

### **Staff Update for Committee on Hepatitis C:**

In the May 2015 PAC meeting, a committee member recommended that the topic of hepatitis C be revisited at the November PAC meeting, and include an update on Medicaid's treatment experience. It was also proposed the department collaborate with a panel of hepatitis C prescribers. On October 21, 2015, the Department held a meeting with 7 of the top 25 prescribers of hepatitis C treatment in the Medicaid program. During this meeting, the Department provided the prescribers with background information on the Medicaid program, information on policy development for hepatitis C drugs, and information on our cost benefit analysis. In addition, clinical staff participated in a discussion with the prescribers regarding options to prioritize treatment. Rachel Currans-Henry provided a report to the Committee on the meeting and additional cost benefit information. Staff will continue to monitor evolving recommendations and pricing strategies for hepatitis C treatment. Additionally, staff will assess recommendations from the hepatitis C prescribers for prior authorization criteria changes, as well as monitor recently released Centers for Medicare and Medicaid Services (CMS) guidance for states regarding access to hepatitis C therapies.

### **Recommendations Summary:**

The following drug classes presented for review had no recommended status changes since the November 5, 2014 Wisconsin Medicaid Pharmacy PA Advisory Committee (PAC) meeting and were approved by the PAC in a block vote. The PAC had no additional discussion regarding these drug classes.

Drug Classes included in the committee block vote:

- Antidepressant, Other
- Antidepressants, SSRIs
- Antihistamines, Minimally Sedating
- Antihypertensives, Sympatholytics
- Antipsoriatics, Oral
- Anxiolytics
- Erythropoiesis Stimulating Proteins
- Histamine II Receptor Blocker
- Immunomodulators, Topical
- Leukotriene Modifiers
- Ophthalmics, Antibiotics
- Ophthalmics, Anti-Inflammatories
- Otic, Anti-Infectives & Anesthetics
- Steroids, Topical Low
- Steroids, Topical Medium
- Steroids, Topical Very High

- Discussion: None
- Kevin Izard made a motion to accept staff recommendations as presented.
  - Second-James Boblin
  - All members were in favor of the motion.
  - Motion passes.

BRONCHODILATORS, BETA AGONIST						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
SEREVENT (INHALATION)	0.1%	OFF	Yes			
FORADIL (INHALATION)	0.3%	ON	Yes			
STRIVERDI RESPIMAT (INHALATION)	0.0%	OFF	No			
ARCAPTA NEOHALER (INHALATION)	0.0%	OFF	No			
ALBUTEROL NEB SOLN 2.5 MG/3 ML (INHALATION)	12.6%	ON	Yes-Gen			
ALBUTEROL NEB SOLN 2.5 MG/0.5 ML (INHALATION)	0.0%	ON	Yes-Gen			
ALBUTEROL NEB SOLN 100 MG/20 ML (INHALATION)	0.2%	ON	Yes-Gen			
ALBUTEROL NEB SOLN 0.63, 1.25 MG (INHALATION)	0.6%	OFF	No-Gen			
XOPENEX NEB SOLN (INHALATION)	0.0%	OFF	No			
XOPENEX NEB SOLN CONC (INHALATION)	0.0%	OFF	No			
LEVALBUTEROL NEB SOLN CONC (INHALATION)	0.0%	OFF	No-Gen			
LEVALBUTEROL NEB SOLN (INHALATION)	0.4%	OFF	No-Gen			
METAPROTERENOL SYRUP (ORAL)	0.0%	OFF	No-Gen			
ALBUTEROL SYRUP (ORAL)	0.1%	ON	Yes-Gen			
METAPROTERENOL TABLET (ORAL)	0.0%	OFF	No-Gen			
TERBUTALINE (ORAL)	0.0%	ON	Yes-Gen			
ALBUTEROL ER (ORAL)	0.0%	ON	Yes-Gen			
ALBUTEROL TABLET (ORAL)	0.0%	ON	Yes-Gen			
PERFORMIST (INHALATION)	0.1%	OFF	No			
BROVANA (INHALATION)	0.1%	OFF	No			
PROVENTIL HFA (INHALATION)	9.7%	ON	Yes			
PROAIR HFA (INHALATION)	74.8%	ON	Yes			
VENTOLIN HFA (INHALATION)	0.6%	OFF	No			
XOPENEX HFA (INHALATION)	0.4%	OFF	No			
PROAIR RESPICLICK (INHALATION)	0.0%	NR	No			

- Discussion: None
- William Raduege made a motion to accept staff recommendations -as presented.
  - Second-Catherine Decker
  - All members were in favor of the motion.
  - Motion passes.

**COPD AGENTS**

Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
IPRATROPIUM NEBULIZER (INHALATION)	2.3%	ON	Yes-Gen			
IPRATROPIUM / ALBUTEROL (INHALATION)	16.6%	ON	Yes-Gen			
ATROVENT HFA (INHALATION)	4.1%	ON	Yes			
SPIRIVA (INHALATION)	49.2%	ON	Yes			
TUDORZA PRESSAIR (INHALATION)	1.0%	OFF	No			
COMBIVENT RESPIMAT (INHALATION)	23.5%	ON	Yes			
INCRUSE ELLIPTA (INHALATION)	0.1%	NR	No			
DALIRESP (ORAL)	2.5%	ON	No			
STIOLTO RESPIMAT (INHALATION)	0.0%	NR	No			
SPIRIVA RESPIMAT (INHALATION)	0.5%	NR	No			
ANORO ELLIPTA (INHALATION)	0.4%	OFF	No			

- Discussion: None
- Pat Towers made a motion to accept staff recommendations as presented.
  - Second-Kevin Izard
  - All members were in favor of the motion.
  - Motion passes.

**GLUCOCORTICOID, INHALED**

Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
DULERA (INHALATION)	5.0%	ON	Yes			
SYMBICORT (INHALATION)	19.1%	ON	Yes			
ADVAIR DISKUS (INHALATION)	36.8%	ON	Yes			
ADVAIR HFA (INHALATION)	0.8%	OFF	No			
BREO ELLIPTA (INHALATION)	0.3%	OFF	No			
ASMANEX (INHALATION)	1.2%	ON	Yes			
QVAR (INHALATION)	7.7%	ON	Yes			
AEROSPAN (INHALATION)	0.0%	OFF	Yes			
ALVESCO (INHALATION)	0.1%	OFF	No			
FLOVENT HFA (INHALATION)	22.2%	ON	No			
PULMICORT FLEXHALER (INHALATION)	1.4%	ON	Yes			
FLOVENT DISKUS (INHALATION)	0.8%	ON	No			
ASMANEX HFA (INHALATION)	0.0%	OFF	No			
ARNIITY ELLIPTA (INHALATION)	0.0%	NR	No			
PULMICORT 0.25, 0.5 MG RESPULES (INHALATION)	1.2%	ON	Yes			
BUDESONIDE 0.25, 0.5 MG RESPULES (INHALATION)	2.9%	OFF	No-Gen			
PULMICORT 1 MG RESPULES (INHALATION)	0.4%	ON	Yes			
BUDESONIDE 1 MG RESPULES (INHALATION)	0.0%	NR	No-Gen			

- Discussion: Catherine Decker expressed concern about the ability to be trained at the pharmacy if multiple devices are used. She expressed concern for the Flovent Diskus going non-preferred. Kimberly Smithers indicated that pharmacies have the ability to perform Medication Therapy Management and be reimbursed for training patients on how to use the devices.
- William Raduege made a motion to accept staff recommendations as presented.
  - Second-Pat Towers
  - All members were in favor of the motion.
  - Motion passes.

GLUCOCORTICOIDS, ORAL						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
PREDNISOLONE SOLUTION (ORAL)	4.6%	ON	Yes-Gen			
PREDNISONE TABLET (ORAL)	68.2%	ON	Yes-Gen			
PREDNISOLONE SODIUM PHOSPHATE (ORAL)	7.5%	ON	Yes-Gen			
DEXAMETHASONE SOLUTION (ORAL)	0.1%	ON	Yes-Gen			
DEXAMETHASONE TABLET (ORAL)	3.3%	ON	Yes-Gen			
METHYLPREDNISOLONE 32 MG TABLET (ORAL)	0.1%	ON	Yes-Gen			
DEXAMETHASONE INTENSOL (ORAL)	0.2%	ON	Yes-Gen			
PREDNISONE SOLUTION (ORAL)	0.3%	ON	Yes-Gen			
ENTOCORT EC (ORAL)	0.7%	ON	No			
DEXAMETHASONE ELIXIR (ORAL)	0.1%	ON	Yes-Gen			
METHYLPREDNISOLONE TAB DS PK (ORAL)	11.0%	ON	Yes-Gen			
ORAPRED ODT (ORAL)	0.4%	ON	Yes			
PREDNISONE TAB DS PK (ORAL)	0.0%	ON	Yes-Gen			
HYDROCORTISONE (ORAL)	2.4%	ON	Yes-Gen			
METHYLPREDNISOLONE TABLET (ORAL)	0.4%	ON	Yes-Gen			
METHYLPREDNISOLONE 16 MG TABLET (ORAL)	0.0%	ON	Yes-Gen			
METHYLPREDNISOLONE 8 MG TABLET (ORAL)	0.0%	ON	Yes-Gen			
PEDIAPRED (ORAL)	0.0%	OFF	No-Gen			
MEDROL TABLET (ORAL)	0.0%	OFF	No			
PREDNISONE INTENSOL (ORAL)	0.0%	ON	Yes-Gen			
CORTEF (ORAL)	0.0%	OFF	No			
CORTISONE (ORAL)	0.0%	OFF	No-Gen			
MILLIPRED SOLUTION (ORAL)	0.0%	OFF	No-Gen			
VERIPRED 20 (ORAL)	0.0%	OFF	No-Gen			
DEXPAK (ORAL)	0.0%	OFF	No-Gen			
PREDNISOLONE SODIUM PHOSPHATE ODT (ORAL)	0.0%	NR	No-Gen			
MILLIPRED DP TAB DS PK (ORAL)	0.0%	OFF	No-Gen			
RAYOS TABLET DR (ORAL)	0.0%	OFF	No			
MILLIPRED TABLET (ORAL)	0.0%	OFF	No-Gen			
BUDESONIDE EC (ORAL)	0.4%	ON	Yes-Gen			

- Discussion: None
- Roseanne Barber made a motion to accept staff recommendations as presented.
  - Second-William Raduege
  - All members were in favor of the motion.
  - Motion passes.

COUGH AND COLD, NARCOTIC

Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
CAPCOF LIQUID (ORAL)	0.0%	OFF	No			
REZIRA SOLUTION (ORAL)	0.0%	OFF	No			
PROMETHAZINE/CODEINE SYRUP (ORAL)	39.9%	ON	Yes-Gen			
GUAIFENESIN/CODEINE LIQUID (ORAL)	30.4%	ON	Yes-Gen			
GUAIFENESIN/CODEINE LIQUID OTC (ORAL)	27.8%	ON	Yes-Gen			
TUSSIONEX SUSPENSION ER 12H (ORAL)	0.0%	OFF	No			
PRO-CLEAR AC LIQUID OTC (ORAL)	0.0%	OFF	No-Gen			
M-END PE LIQUID (ORAL)	0.0%	OFF	No-Gen			
M-CLEAR WC LIQUID (ORAL)	0.0%	ON	Yes-Gen			
HYDROCODONE/HOMATROPINE SYRUP (ORAL)	0.0%	OFF	No-Gen			
PSE/CODEINE/CHLORPHENIRAMINE LIQUID OTC (ORAL)	0.0%	OFF	No-Gen			
NINJACOF-XG LIQUID OTC (ORAL)	0.0%	NR	No-Gen			
PROMETHAZINE/PHENYLEPHRINE/CODEINE SYRUP (ORAL)	0.0%	ON	Yes-Gen			
TUSNEL C SYRUP OTC (ORAL)	0.0%	OFF	No-Gen			
PSE/HYDROCODONE/CHLORPHENIRAMINE SOLUTION (ORAL)	0.0%	OFF	No-Gen			
PROMETHAZINE/PHENYLEPHRINE/CODEINE (QUALITEST) SYRUP (ORAL)	1.3%	ON	Yes-Gen			
HYDROCODONE/CHLORPHENIRAMINE SUSPENSION ER 12H (ORAL)	0.6%	OFF	No-Gen			
ZUTRIPRO SOLUTION (ORAL)	0.0%	OFF	No			
VITUZ SOLUTION (ORAL)	0.0%	OFF	No			
FLOWTUSS SOLUTION (ORAL)	0.0%	NR	No			
HYCOFENIX SOLUTION (ORAL)	0.0%	NR	No			

- Discussion: None
- John Fangman made a motion to accept staff recommendations as presented.
  - Second-Steve Maike
  - All members were in favor of the motion.
  - Motion passes.

EPINEPHRINE, SELF-INJECTED

Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
AUVI-Q (INTRAMUSC)	0.3%	OFF	No			
ADRENACLICK (INTRAMUSC)	0.0%	NR	No			
EPINEPHRINE (ADRENACLICK) (AG) (INJECTION)	0.0%	OFF	No-Gen			
EPIPEN (INTRAMUSC)	76.9%	ON	Yes			
EPIPEN JR (INTRAMUSC)	22.8%	ON	Yes			

- Discussion: None
- Catherine Decker made a motion to accept staff recommendations as presented.
  - Second-William Raduege
  - All members were in favor of the motion.
  - Motion passes.

**INTRANASAL RHINITIS AGENTS**

Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
PATANASE (NASAL)	1.0%	ON	Yes			
OLOPATADINE (AG) (NASAL)	0.0%	NR	No-Gen			
AZELASTINE (ASTELIN) (NASAL)	0.1%	OFF	No-Gen			
AZELASTINE (ASTEPRO) (AG) (NASAL)	0.0%	OFF	No-Gen			
AZELASTINE (ASTEPRO) (NASAL)	0.0%	OFF	No-Gen			
ASTEPRO (NASAL)	1.6%	ON	No			
OLOPATADINE (NASAL)	0.0%	NR	No-Gen			
IPRATROPIUM (NASAL)	1.8%	ON	Yes-Gen			
OMNARIS (NASAL)	0.1%	OFF	No			
ZETONNA (NASAL)	0.1%	OFF	No			
FLUTICASONE (NASAL)	81.4%	ON	Yes-Gen			
NASACORT OTC (NASAL)	0.0%	OFF	No			
NASONEX (NASAL)	12.8%	ON	Yes			
BECONASE AQ (NASAL)	0.3%	ON	Yes			
QNASL 80 (NASAL)	0.2%	OFF	No			
QNASL 40 (NASAL)	0.0%	OFF	No			
VERAMYST (NASAL)	0.3%	OFF	No			
DYMISTA (NASAL)	0.1%	OFF	No			
FLUNISOLIDE (NASAL)	0.0%	OFF	No-Gen			
TRIAMCINOLONE (NASAL)	0.1%	OFF	No-Gen			
BUDESONIDE (NASAL)	0.1%	OFF	No-Gen			
BUDESONIDE (AG) (NASAL)	0.0%	OFF	No-Gen			
RHINOCORT AQUA (NASAL)	0.1%	OFF	No			

- Discussion: None
- John Fangman made a motion to accept staff recommendations as presented.
  - Second-Pat Towers
  - All members were in favor of the motion.
  - Motion passes.

**ANTHYPERURICEMICS**

Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ALLOPURINOL (ORAL)	81.1%	ON	Yes-Gen			
PROBENECID / COLCHICINE (ORAL)	3.4%	ON	Yes-Gen			
ULORIC (ORAL)	6.4%	OFF	No			
PROBENECID (ORAL)	1.2%	ON	Yes-Gen			
COLCHICINE CAPSULE (AG) (ORAL)	0.0%	NR	No-Gen			
COLCHICINE TABLET (AG) (ORAL)	5.5%	NR	No-Gen			
COLCRYS (ORAL)	2.4%	OFF	No			

- Discussion: None
- John Fangman made a motion to accept staff recommendations as presented.
  - Second-William Raduege
  - All members were in favor of the motion.
  - Motion passes.



BILE SALTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
URSODIOL TABLET (ORAL)	21.6%	ON	Yes-Gen			
URSODIOL 300 MG CAPSULE (ORAL)	78.4%	ON	Yes-Gen			
CHOLBAM (ORAL)	0.0%	NR	No			
CHENODAL (ORAL)	0.0%	OFF	No-Gen			

- Discussion: None
- Pat Towers made a motion to accept staff recommendations as presented.
  - Second-John Fangman
  - All members were in favor of the motion.
  - Motion passes.

OPHTHALMIC ANTIBIOTIC-STERIOD COMBINATIONS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
PRED-G DROPS SUSP (OPHTHALMIC)	0.3%	ON	Yes			
TOBRADEX OINTMENT (OPHTHALMIC)	13.2%	ON	Yes			
SULFACETAMIDE / PREDNISOLONE (OPHTHALMIC)	2.5%	ON	Yes-Gen			
NEOMYCIN/POLYMYXIN/DEXAMETHASONE (OPHTHALMIC)	50.9%	ON	Yes-Gen			
BLEPHAMIDE (OPHTHALMIC)	2.0%	ON	Yes			
PRED-G OINT. (OPHTHALMIC)	0.1%	ON	Yes			
ZYLET (OPHTHALMIC)	0.0%	OFF	No			
TOBRADEX SUSPENSION (OPHTHALMIC)	29.9%	ON	Yes			
TOBRAMYCIN / DEXAMETHASONE SUSPENSION (AG) (OPHTHALMIC)	0.1%	OFF	No-Gen			
NEOMYCIN/BACITRACIN/POLY/HC (OPHTHALMIC)	0.0%	OFF	No-Gen			
TOBRADEX ST (OPHTHALMIC)	0.0%	OFF	No			
TOBRAMYCIN / DEXAMETHASONE SUSPENSION (OPHTHALMIC)	0.1%	OFF	No-Gen			
BLEPHAMIDE S.O.P. (OPHTHALMIC)	1.0%	ON	No-Gen			
NEOMYCIN/POLYMYXIN/HC (OPHTHALMIC)	0.0%	OFF	No-Gen			

- Discussion: None
- Steve Maike made a motion to accept staff recommendations as presented.
  - Second-William Raduege
  - All members were in favor of the motion.
  - Motion passes.

OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS

Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
BEPREVE (OPHTHALMIC)	0.1%	OFF	No			
ALREX (OPHTHALMIC)	1.5%	ON	Yes			
PATANOL (OPHTHALMIC)	0.5%	OFF	No			
ZADITOR OTC (OPHTHALMIC)	1.1%	ON	Yes-Gen			
KETOTIFEN OTC (OPHTHALMIC)	15.1%	ON	Yes-Gen			
PAZEO (OPHTHALMIC)	0.0%	NR	Yes			
PATADAY (OPHTHALMIC)	78.6%	ON	Yes			
EMADINE (OPHTHALMIC)	0.0%	OFF	No			
AZELASTINE (OPHTHALMIC)	0.0%	OFF	No-Gen			
EPINASTINE (OPHTHALMIC)	0.1%	OFF	No-Gen			
LASTACFT (OPHTHALMIC)	0.2%	OFF	No			
CROMOLYN SODIUM (OPHTHALMIC)	2.9%	ON	Yes-Gen			
ALOMIDE (OPHTHALMIC)	0.0%	OFF	No			
ALOCRIL (OPHTHALMIC)	0.0%	OFF	No			

- Discussion: Rachel Currans-Henry noted that the recommendation to prefer Pazeo was not due to any patent expirations but rather due to product pricing being favorable to the State. Rick Pope stated that the patents on the other products do not expire for 4 to 5 years.
- William Raduege made a motion to accept staff recommendations as presented.
  - Second-John Fangman
  - All members were in favor of the motion.
  - Motion passes.

OPHTHALMICS, GLAUCOMA AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
BRIMONIDINE (OPHTHALMIC)	4.5%	ON	Yes-Gen			
ALPHAGAN P 0.15% (OPHTHALMIC)	3.8%	ON	Yes			
ALPHAGAN P 0.1% (OPHTHALMIC)	0.3%	OFF	No			
APRACLONIDINE (OPHTHALMIC)	0.0%	OFF	No-Gen			
BRIMONIDINE P 0.15% (OPHTHALMIC)	0.0%	OFF	No-Gen			
IOPIDINE (OPHTHALMIC)	0.0%	OFF	No			
BETIMOL (OPHTHALMIC)	0.1%	ON	Yes			
CARTEOLOL (OPHTHALMIC)	0.1%	ON	Yes-Gen			
BETOPTIC S (OPHTHALMIC)	0.5%	ON	Yes			
ISTALOL (OPHTHALMIC)	0.0%	OFF	No			
TIMOLOL (OPHTHALMIC)	13.3%	ON	Yes-Gen			
COMBIGAN (OPHTHALMIC)	6.2%	ON	Yes			
LEVOBUNOLOL (OPHTHALMIC)	0.7%	ON	Yes-Gen			
BETAXOLOL (OPHTHALMIC)	0.1%	ON	No-Gen			
METIPRANOLOL (OPHTHALMIC)	0.0%	ON	No-Gen			
TIMOPTIC OCUDOSE (OPHTHALMIC)	0.0%	OFF	No			
AZOPT (OPHTHALMIC)	2.6%	ON	Yes			
DORZOLAMIDE / TIMOLOL (OPHTHALMIC)	7.0%	ON	Yes-Gen			
SIMBRINZA (OPHTHALMIC)	1.0%	ON	Yes			
DORZOLAMIDE (OPHTHALMIC)	2.9%	ON	Yes-Gen			
COSOPT PF (OPHTHALMIC)	0.3%	ON	No			
TRAVATAN Z 2.5 ML (OPHTHALMIC)	21.0%	ON	Yes			
TRAVATAN Z 5 ML (OPHTHALMIC)	2.9%	ON	Yes			
LATANOPROST 2.5 ML (OPHTHALMIC)	30.3%	ON	Yes-Gen			
LUMIGAN 2.5ML (OPHTHALMIC)	1.0%	OFF	No			
LUMIGAN 5ML (OPHTHALMIC)	0.1%	OFF	No			
TRAVOPROST 2.5 ML (OPHTHALMIC)	0.0%	OFF	No-Gen			
BIMATOPROST 2.5ML (OPHTHALMIC)	0.0%	OFF	No-Gen			
ZIOPTAN (OPHTHALMIC)	0.3%	OFF	No			
TRAVOPROST 5 ML (OPHTHALMIC)	0.0%	OFF	No-Gen			
BIMATOPROST 5ML (OPHTHALMIC)	0.0%	OFF	No-Gen			
BIMATOPROST 7.5ML (OPHTHALMIC)	0.0%	OFF	No-Gen			
PILOCARPINE (OPHTHALMIC)	0.8%	ON	Yes-Gen			

- Discussion: None
- Kevin Izard made a motion to accept staff recommendations as presented.
  - Second-John Fangman
  - All members were in favor of the motion.
  - Motion passes.

**OTIC ANTIBIOTICS**

Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
COLY-MYCIN S (OTIC)	0.1%	ON	Yes			
CIPRO HC (OTIC)	20.1%	ON	Yes			
OFLOXACIN (OTIC)	37.4%	ON	No-Gen			
NEOMYCIN/POLYMYXIN/HC SOLN/SUSP (OTIC)	39.7%	ON	Yes-Gen			
CIPRODEX (OTIC)	2.7%	OFF	No			
CORTISPORIN-TC (OTIC)	0.0%	OFF	No			
CIPROFLOXACIN (OTIC)	0.0%	ON	Yes-Gen			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
  - Second-Pat Towers
  - All members were in favor of the motion.
  - Motion passes.

**ANTIPSORIATICS, TOPICAL**

Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
VECTICAL (TOPICAL)	4.1%	ON	Yes			
SORILUX (TOPICAL)	0.0%	OFF	No			
CALCIPOTRIENE SOLUTION (TOPICAL)	7.7%	ON	Yes-Gen			
TACLONEX SCALP (TOPICAL)	10.6%	ON	Yes			
CALCITRENE (TOPICAL)	5.1%	ON	Yes-Gen			
CALCITRIOL OINTMENT (TOPICAL)	0.0%	OFF	No-Gen			
CALCIPOTRIENE OINTMENT (TOPICAL)	3.1%	OFF	Yes-Gen			
CALCIPOTRIENE CREAM (TOPICAL)	59.2%	ON	Yes-Gen			
CALCIPOTRIENE/BETAMETHASONE OINTMENT (AG) (TOPICAL)	0.5%	OFF	No			
CALCIPOTRIENE/BETAMETHASONE OINTMENT (TOPICAL)	0.2%	OFF	No-Gen			
TACLONEX OINTMENT (TOPICAL)	9.4%	ON	No			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
  - Second-John Fangman
  - All members were in favor of the motion.
  - Motion passes.

IMMUNOMODULATORS, ATOPIC DERMATITIS

Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ELIDEL (TOPICAL)	91.7%	ON	Yes			
PROTOPIC (TOPICAL)	2.0%	OFF	No			
TACROLIMUS (AG) (TOPICAL)	5.9%	NR	No-Gen			
TACROLIMUS (TOPICAL)	0.4%	NR	No-Gen			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
  - Second-Steve Maike
  - All members were in favor of the motion.
  - Motion passes.

STEROIDS, TOPICAL HIGH

Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
BETAMET DIPROP / PROP GLY CREAM (TOPICAL)	0.0%	OFF	No-Gen			
TRIAMCINOLONE ACETONIDE CREAM (TOPICAL)	50.4%	ON	Yes-Gen			
TRIAMCINOLONE ACETONIDE OINTMENT (TOPICAL)	32.4%	ON	Yes-Gen			
TRIAMCINOLONE ACETONIDE LOTION (TOPICAL)	1.0%	ON	Yes-Gen			
BETAMETHASONE VALERATE OINTMENT (TOPICAL)	2.6%	ON	Yes-Gen			
BETAMETHASONE DIPROPIONATE LOTION (TOPICAL)	0.0%	OFF	No-Gen			
BETAMETHASONE VALERATE CREAM (TOPICAL)	3.3%	ON	Yes-Gen			
BETAMETHASONE VALERATE LOTION (TOPICAL)	1.2%	ON	Yes-Gen			
FLUOCINONIDE SOLUTION (TOPICAL)	1.4%	ON	No-Gen			
FLUOCINONIDE GEL (TOPICAL)	0.3%	ON	No-Gen			
BETAMETHASONE DIPROPIONATE CREAM (TOPICAL)	0.2%	OFF	No-Gen			
BETAMET DIPROP / PROP GLY OINTMENT (TOPICAL)	0.1%	OFF	No-Gen			
BETAMETHASONE DIPROPIONATE OINTMENT (TOPICAL)	0.1%	OFF	No-Gen			
BETAMETHASONE DIPROPIONATE GEL (TOPICAL)	0.0%	OFF	No-Gen			
FLUOCINONIDE EMOLLIENT (TOPICAL)	0.4%	ON	No-Gen			
FLUOCINONIDE CREAM (TOPICAL)	2.8%	ON	No-Gen			
BETAMET DIPROP / PROP GLY LOTION (TOPICAL)	0.0%	OFF	No-Gen			
TOPICORT OINTMENT (TOPICAL)	0.0%	OFF	No			
KENALOG AEROSOL (TOPICAL)	0.0%	OFF	No			
DESOXIMETASONE CREAM (TOPICAL)	0.0%	OFF	No-Gen			
DIFLORASONE DIACETATE OINTMENT (TOPICAL)	0.0%	OFF	No-Gen			
TRIAMCINOLONE ACETONIDE AEROSOL (TOPICAL)	0.0%	NR	No-Gen			
TOPICORT SPRAY (TOPICAL)	0.0%	OFF	No			
FLUOCINONIDE OINTMENT (TOPICAL)	3.7%	ON	No-Gen			
DESOXIMETASONE GEL (TOPICAL)	0.0%	OFF	No-Gen			
AMCINONIDE LOTION (TOPICAL)	0.0%	OFF	No-Gen			
HALOG OINTMENT (TOPICAL)	0.0%	OFF	No			
HALOG CREAM (TOPICAL)	0.0%	OFF	No			
DESOXIMETASONE OINTMENT (TOPICAL)	0.1%	OFF	No-Gen			
AMCINONIDE OINTMENT (TOPICAL)	0.0%	OFF	No-Gen			
AMCINONIDE CREAM (TOPICAL)	0.0%	OFF	No-Gen			
TRIANEX OINTMENT (TOPICAL)	0.0%	OFF	No-Gen			
DIFLORASONE DIACETATE CREAM (TOPICAL)	0.0%	OFF	No-Gen			
VANOS (TOPICAL)	0.0%	OFF	No			

- Discussion: None
- Roseanne Barber made a motion to accept staff recommendations as presented.
  - Second-Pat Towers
  - All members were in favor of the motion.
  - Motion passes.

CYTOKINE AND CAM ANTAGONISTS

Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
SIMPONI SYRINGE (INJECTION)	0.1%	OFF	No			
SIMPONI PEN INJECTER (INJECTION)	0.7%	OFF	No			
ENBREL KIT (INJECTION)	1.3%	ON	Yes			
KINERET (INJECTION)	0.5%	OFF	No			
HUMIRA PEN KIT (INJECTION)	52.8%	ON	Yes			
HUMIRA KIT (INJECTION)	6.5%	ON	Yes			
CIMZIA SYRINGE KIT (INJECTION)	6.1%	ON	No			
ENBREL SYRINGE (INJECTION)	6.4%	ON	Yes			
ENBREL PEN (INJECTION)	20.7%	ON	Yes			
CIMZIA KIT (INJECTION)	0.3%	ON	No			
ORENCIA SYRINGE (SUBCUTANE.)	1.9%	OFF	No			
XELJANZ (ORAL)	1.0%	OFF	No			
OTEZLA (ORAL)	0.4%	OFF	No			
ACTEMRA SYRINGE (SUBCUTANE.)	0.6%	OFF	No			
COSENTYX PEN INJECTER (SUBCUTANE.)	0.1%	NR	No			
COSENTYX SYRINGE (SUBCUTANE.)	0.0%	NR	No			
STELARA SYRINGE (INJECTION)	0.8%	OFF	No			

- Discussion: Rachel Currans-Henry indicated there was discussion in closed session regarding drugs being preferred or non-preferred based on disease state. With these recommendations, we will have two drugs preferred in most disease states.
- John Fangman made a motion to accept staff recommendations as presented.
  - Second-William Radeuge
  - All members were in favor of the motion.
  - Motion passes.

## NSAIDS

Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
IBUPROFEN TABLET OTC (ORAL)	1.3%	ON	Yes-Gen			
MELOXICAM TABLET (ORAL)	15.8%	ON	Yes-Gen			
ADVIL OTC (ORAL)	0.0%	ON	Yes-Gen			
CELEBREX (ORAL)	0.3%	OFF	No			
INDOMETHACIN CAPSULE (ORAL)	2.0%	ON	Yes-Gen			
IBUPROFEN TABLET (ORAL)	32.4%	ON	Yes-Gen			
NAPROXEN SODIUM OTC (ORAL)	0.5%	ON	Yes-Gen			
NAPROXEN TABLET (ORAL)	14.4%	ON	Yes-Gen			
MOBIC SUSPENSION (ORAL)	0.0%	OFF	No			
ADVIL MIGRAINE CAPSULE OTC (ORAL)	0.0%	ON	Yes			
IBUPROFEN CAPSULE OTC (ORAL)	0.0%	ON	Yes-Gen			
IBUPROFEN TAB CHEW OTC (ORAL)	0.0%	ON	Yes-Gen			
VOLTAREN (TOPICAL)	6.0%	ON	Yes			
ADVIL TAB CHEW OTC (ORAL)	0.0%	ON	Yes			
NAPROXEN SODIUM (ORAL)	1.0%	ON	Yes-Gen			
DICLOFENAC SR (ORAL)	0.2%	ON	Yes-Gen			
IBUPROFEN DROPS SUSPENSION OTC (ORAL)	0.0%	ON	Yes-Gen			
NAPROXEN EC (ORAL)	0.5%	ON	Yes-Gen			
IBUPROFEN SUSPENSION OTC (ORAL)	0.9%	ON	Yes-Gen			
IBUPROFEN SUSPENSION (ORAL)	8.1%	ON	Yes-Gen			
SULINDAC (ORAL)	0.4%	ON	Yes-Gen			
KETOROLAC (ORAL)	1.8%	ON	Yes-Gen			
FLURBIPROFEN (ORAL)	0.1%	ON	Yes-Gen			
DICLOFENAC SODIUM (ORAL)	7.7%	ON	Yes-Gen			
MELOXICAM SUSPENSION (ORAL)	0.0%	OFF	No-Gen			
NABUMETONE (ORAL)	1.6%	ON	Yes-Gen			
NAPROXEN SUSPENSION (ORAL)	0.1%	ON	Yes-Gen			
NAPRELAN (ORAL)	0.0%	OFF	No			
DUEXIS (ORAL)	0.0%	OFF	No			
INDOCIN SUSPENSION (ORAL)	0.0%	OFF	No			
KETOPROFEN (ORAL)	0.0%	ON	Yes-Gen			
VIMOVO (ORAL)	0.0%	OFF	No			
INDOCIN (RECTAL)	0.0%	OFF	No-Gen			
DICLOFENAC POTASSIUM (ORAL)	0.9%	ON	Yes-Gen			
PENNSAID SOLUTION (TOPICAL)	0.0%	OFF	No			
ETODOLAC (ORAL)	0.1%	OFF	No-Gen			
TIVORBEX (ORAL)	0.0%	NR	No			
OXAPROZIN (ORAL)	0.0%	OFF	No-Gen			
NALFON (ORAL)	0.0%	OFF	No			
DIFLUNISAL (ORAL)	0.0%	OFF	No-Gen			
FLECTOR (TOPICAL)	0.1%	OFF	No			
PIROXICAM (ORAL)	0.1%	OFF	No-Gen			
SPRIX (NASAL)	0.0%	OFF	No			
FENOPROFEN (ORAL)	0.0%	OFF	No-Gen			
ZIPSOR (ORAL)	0.0%	OFF	No			
INDOMETHACIN CAPSULE ER (ORAL)	0.0%	OFF	No-Gen			
TOLMETIN SODIUM CAPSULE (ORAL)	0.0%	OFF	No-Gen			
DICLOFENAC SODIUM/MISOPROSTOL (ORAL)	0.0%	OFF	No-Gen			
ZORVOLEX (ORAL)	0.0%	OFF	No			
CELECOXIB (ORAL)	2.9%	NR	No-Gen			
ETODOLAC TAB SR (ORAL)	0.0%	OFF	No-Gen			
NAPROXEN CR (ORAL)	0.0%	NR	No-Gen			
FENOPROFEN (AG) (ORAL)	0.0%	OFF	No-Gen			
KETOPROFEN ER (ORAL)	0.0%	OFF	No-Gen			
MECLOFENAMATE (ORAL)	0.0%	OFF	No-Gen			
TOLMETIN SODIUM TABLET (ORAL)	0.0%	OFF	No-Gen			
CELECOXIB (AG) (ORAL)	0.5%	NR	No-Gen			
DICLOFENAC SOLUTION (TOPICAL)	0.0%	OFF	No-Gen			
MEFENAMIC ACID (ORAL)	0.0%	OFF	No-Gen			
PENNSAID PUMP (TOPICAL)	0.0%	OFF	No			
PONSTEL (ORAL)	0.0%	OFF	No			



- Discussion: None
- Pat Towers made a motion to accept staff recommendations as presented.
  - Second-James Boblin
  - All members were in favor of the motion.
  - Motion passes.

NEUROPATHIC PAIN						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
GABAPENTIN CAPSULE (ORAL)	42.8%	ON	Yes-Gen			
DULOXETINE (CYMBALTA) (AG) (ORAL)	0.0%	ON	Yes-Gen			
GABAPENTIN TABLET (ORAL)	13.4%	ON	Yes-Gen			
GRALISE (ORAL)	0.0%	OFF	No			
DULOXETINE (CYMBALTA) (ORAL)	21.0%	ON	Yes-Gen			
LYRICA CAPSULE (ORAL)	15.6%	ON	Yes			
SAVELLA DOSE PACK (ORAL)	0.1%	ON	Yes			
SAVELLA (ORAL)	1.1%	ON	Yes			
GABAPENTIN SOLUTION (ORAL)	0.5%	ON	Yes-Gen			
HORIZANT (ORAL)	0.0%	OFF	No			
DULOXETINE (IRENKA) (ORAL)	0.0%	NR	No-Gen			
IRENKA (ORAL)	0.0%	NR	No			
LYRICA SOLUTION (ORAL)	0.0%	ON	Yes			
CAPSAICIN OTC (TOPICAL)	0.2%	ON	Yes-Gen			
ZOSTRIX OTC (TOPICAL)	0.0%	ON	Yes-Gen			
LIDODERM (TOPICAL)	5.1%	ON	Yes			
LIDOCAINE (AG) (TOPICAL)	0.0%	OFF	No-Gen			
LIDOCAINE (TOPICAL)	0.0%	OFF	No-Gen			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
  - Second-John Fangman
  - All members were in favor of the motion.
  - Motion passes.

ALZHEIMER'S AGENTS

Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
DONEPEZIL TABLET (ORAL)	59.3%	ON	Yes-Gen			
MEMANTINE TABLET DOSE PACK (AG) (ORAL)	0.0%	NR	Yes-Gen			
MEMANTINE TABLET (AG) (ORAL)	0.4%	NR	Yes-Gen			
MEMANTINE TABLET (ORAL)	1.6%	NR	Yes-Gen			
NAMENDA TABLET DOSE PACK (ORAL)	0.2%	ON	No			
GALANTAMINE ER (ORAL)	0.8%	OFF	No-Gen			
EXELON (TRANSDERM.)	4.5%	ON	Yes			
NAMENDA TABLET (ORAL)	26.2%	ON	No			
EXELON CAPSULES (ORAL)	0.1%	OFF	No			
GALANTAMINE TABLET (ORAL)	0.4%	OFF	No-Gen			
NAMENDA XR (ORAL)	3.9%	OFF	No			
GALANTAMINE SOLUTION (ORAL)	0.0%	OFF	No-Gen			
NAMZARIC (ORAL)	0.0%	NR	No			
RIVASTIGMINE CAPSULES (ORAL)	1.6%	ON	Yes-Gen			
ARICEPT 23 MG (ORAL)	0.0%	OFF	No			
NAMENDA SOLUTION (ORAL)	0.1%	ON	Yes			
DONEPEZIL ODT (ORAL)	0.2%	ON	Yes-Gen			
DONEPEZIL 23 MG (ORAL)	0.5%	OFF	No-Gen			
RIVASTIGMINE (TRANSDERM.)	0.0%	NR	No-Gen			
RIVASTIGMINE (AG) (TRANSDERM.)	0.0%	NR	No-Gen			

- Discussion: None
- James Boblin made a motion to accept staff recommendations as presented.
  - Second-Steve Maike
  - All members were in favor of the motion.
  - Motion passes.

ANTICONVULSANTS

Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
TOPIRAMATE ER (AG) (ORAL)	0.0%	OFF	No-Gen			
CLONAZEPAM (ORAL)	25.3%	ON	Yes-Gen			
TOPIRAMATE TABLETS (ORAL)	13.0%	ON	Yes-Gen			
PRIMIDONE (ORAL)	1.0%	ON	Yes-Gen			
LAMOTRIGINE TABLET (ORAL)	18.6%	ON	Yes-Gen			
VALPROATE SYRUP (ORAL)	0.9%	ON	Yes-Gen			
LAMICTAL TABLET DOSE PACK (ORAL)	0.1%	ON	Yes			
LEVETIRACETAM TABLETS (ORAL)	7.0%	ON	Yes-Gen			
OXCARBAZEPINE TABLETS (ORAL)	2.9%	ON	Yes-Gen			
CELONTIN (ORAL)	0.0%	ON	Yes			
DIVALPROEX TABLET (ORAL)	4.6%	ON	Yes-Gen			
ZONISAMIDE (ORAL)	1.7%	ON	Yes-Gen			
LEVETIRACETAM SOLUTION (ORAL)	2.5%	ON	Yes-Gen			
TEGRETOL TABLET (ORAL)	0.1%	NR	Yes			
VALPROIC ACID (ORAL)	0.1%	ON	Yes-Gen			
TEGRETOL SUSPENSION (ORAL)	0.0%	NR	Yes			
GABTRIL (ORAL)	0.1%	ON	Yes			
DEPAKOTE SPRINKLE (ORAL)	1.4%	ON	Yes			
PHENYTOIN SUSPENSION (ORAL)	0.1%	ON	Yes-Gen			
CARBAMAZEPINE CHEWABLE TABLET (ORAL)	0.5%	ON	Yes-Gen			
LEVETIRACETAM ER (ORAL)	0.5%	ON	Yes-Gen			
PHENOBARBITAL TABLET (ORAL)	0.9%	ON	Yes-Gen			
PHENYTOIN EXT CAPSULE (GENERIC PHENYTEK) (ORAL)	0.0%	ON	Yes-Gen			
PHENYTOIN CHEWABLE TABLET (ORAL)	0.2%	ON	Yes-Gen			
PHENYTOIN CAPSULE (ORAL)	1.4%	ON	Yes-Gen			
CLONAZEPAM ODT (ORAL)	0.1%	OFF	No-Gen			
TEGRETOL XR (ORAL)	0.7%	ON	Yes			
PEGANONE (ORAL)	0.0%	ON	Yes			
EQUETRO (ORAL)	0.0%	OFF	No			
PHENYTEK (ORAL)	0.0%	OFF	No-Gen			
CARBAMAZEPINE TABLET (ORAL)	2.2%	ON	No-Gen			
DILANTIN INFATAB (ORAL)	0.1%	ON	Yes-Gen			
CARBATROL (ORAL)	0.3%	ON	Yes			
LAMICTAL ODT DOSE PACK (ORAL)	0.0%	OFF	No			
PHENOBARBITAL ELIXIR (ORAL)	0.4%	ON	Yes-Gen			
DIASTAT (RECTAL)	0.0%	ON	Yes			
CARBAMAZEPINE SUSPENSION (ORAL)	0.2%	ON	No-Gen			
ETHOSUXIMIDE CAPSULE (ORAL)	0.2%	ON	Yes-Gen			
CARBAMAZEPINE ER (GENERIC CARBATROL) (ORAL)	0.8%	ON	Yes-Gen			
CARBAMAZEPINE XR (ORAL)	0.1%	OFF	No-Gen			
ETHOSUXIMIDE SYRUP (ORAL)	0.2%	ON	Yes-Gen			
LAMOTRIGINE TABLET DOSE PACK (ORAL)	0.0%	ON	Yes-Gen			
DIVALPROEX ER (ORAL)	6.9%	ON	Yes-Gen			
DIVALPROEX SPRINKLE (ORAL)	0.1%	OFF	No-Gen			
TOPIRAMATE SPRINKLE (ORAL)	0.3%	ON	Yes-Gen			
DIASTAT ACUDIAL (RECTAL)	0.4%	ON	Yes			
QUDEXY XR (ORAL)	0.0%	OFF	No			
OXCARBAZEPINE SUSPENSION (ORAL)	0.4%	ON	Yes-Gen			
TRILEPTAL SUSPENSION (ORAL)	0.1%	ON	No			
LAMICTAL ODT (ORAL)	0.1%	OFF	No			
DIAZEPAM (RECTAL)	0.0%	OFF	No-Gen			
VIMPAT TABLET (ORAL)	0.8%	OFF	No			
OXTELLAR XR (ORAL)	0.0%	OFF	No			
TIAGABINE (ORAL)	0.0%	OFF	No-Gen			
VIMPAT SOLUTION (ORAL)	0.1%	OFF	No			
ONFI TABLET (ORAL)	0.6%	OFF	No			
POTIGA (ORAL)	0.0%	OFF	No			
DIAZEPAM DEVICE (RECTAL)	0.0%	OFF	No-Gen			
TROKENDI XR (ORAL)	0.0%	OFF	No			
LAMOTRIGINE ODT (ORAL)	0.0%	NR	No-Gen			
BANZEL TABLET (ORAL)	0.2%	OFF	No			
ONFI SUSPENSION (ORAL)	0.2%	OFF	No			
FELBAMATE TABLET (ORAL)	0.0%	OFF	Yes-Gen			
FYCOMPA (ORAL)	0.0%	OFF	No			
LAMICTAL XR DOSE PACK (ORAL)	0.0%	OFF	No			
LAMOTRIGINE XR (ORAL)	0.5%	OFF	No-Gen			
LAMICTAL XR (ORAL)	0.2%	OFF	No			
APTiom (ORAL)	0.0%	OFF	No			
FELBAMATE SUSPENSION (ORAL)	0.0%	OFF	Yes-Gen			
BANZEL SUSPENSION (ORAL)	0.0%	OFF	No			
FELBATOL TABLET (ORAL)	0.3%	ON	No			
FELBATOL SUSPENSION (ORAL)	0.3%	ON	No			
SABRIL POWDER PACK (ORAL)	0.0%	OFF	No			
SABRIL TABLET (ORAL)	0.0%	OFF	No			

- Discussion: Kevin Izard stated prescribers are concerned about members changing from generic to brand and brand to generic for Narrow Therapeutic Index (NTI) drugs, such as the anticonvulsants. He also stated concern with the ability to grandfather but recognized the potential savings that can be had by preferring brands.
- James Boblin made a motion to accept staff recommendations as presented.
  - Second-Pat Towers
  - All members were in favor of the motion.
  - Motion passes.

ANTIPARKINSON'S AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ROPINIROLE (ORAL)	27.5%	ON	Yes-Gen			
BENZTROPINE (ORAL)	33.5%	ON	Yes-Gen			
PRAMIPEXOLE (ORAL)	13.7%	ON	Yes-Gen			
MIRAPEX ER (ORAL)	0.0%	OFF	No			
TRIHEXYPHENIDYL TABLET (ORAL)	4.8%	ON	Yes-Gen			
CARBIDOPA / LEVODOPA (ORAL)	11.7%	ON	Yes-Gen			
TRIHEXYPHENIDYL ELIXIR (ORAL)	0.1%	ON	Yes-Gen			
CARBIDOPA / LEVODOPA ER (ORAL)	2.6%	ON	Yes-Gen			
SELEGILINE CAPSULE (ORAL)	0.2%	ON	Yes-Gen			
AMANTADINE SYRUP (ORAL)	0.2%	ON	Yes-Gen			
NEUPRO (TRANSDERM)	0.3%	OFF	No			
SELEGILINE TABLET (ORAL)	0.0%	ON	Yes-Gen			
CARBIDOPA / LEVODOPA ODT (ORAL)	0.2%	ON	Yes-Gen			
AMANTADINE TABLET (ORAL)	1.5%	ON	Yes-Gen			
AMANTADINE CAPSULE (ORAL)	1.9%	ON	Yes-Gen			
REQUIP XL (ORAL)	0.0%	OFF	No			
AZILECT (ORAL)	0.3%	OFF	No			
ZELAPAR (ORAL)	0.0%	OFF	No			
BROMOCRIPTINE (ORAL)	0.8%	ON	Yes-Gen			
COMTAN (ORAL)	0.0%	OFF	No			
ROPINIROLE ER (ORAL)	0.1%	OFF	No-Gen			
CARBIDOPA/LEVODOPA/ENTACAPONE (ORAL)	0.0%	OFF	Yes-Gen			
STALEVO (ORAL)	0.2%	ON	No			
ENTACAPONE (ORAL)	0.2%	OFF	No-Gen			
CARBIDOPA (ORAL)	0.1%	OFF	No-Gen			
PRAMIPEXOLE ER (ORAL)	0.0%	OFF	No-Gen			
RYTARY (ORAL)	0.1%	NR	No			
TASMAR (ORAL)	0.0%	OFF	No			
LODOSYN (ORAL)	0.1%	ON	Yes			
TOLCAPONE (ORAL)	0.0%	OFF	No-Gen			

- Discussion: None
- James Boblin made a motion to accept staff recommendations as presented.
  - Second-John Fangman
  - All members were in favor of the motion.
  - Motion passes.

ANTIPSYCHOTICS

Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
RISPERIDONE TABLET (ORAL)	19.9%	ON	Yes-Gen			
HALOPERIDOL LACTATE CONC (ORAL)	0.0%	ON	Yes-Gen			
QUETIAPINE TABLETS (ORAL)	29.0%	ON	Yes-Gen			
OLANZAPINE TABLET (ORAL)	7.8%	ON	Yes-Gen			
FLUPHENAZINE TABLET (ORAL)	0.8%	ON	Yes-Gen			
ORAP (ORAL)	0.1%	ON	Yes			
HALOPERIDOL (ORAL)	3.2%	ON	Yes-Gen			
FAZACLO (ORAL)	0.0%	OFF	No			
LOXAPINE (ORAL)	0.4%	ON	Yes-Gen			
THIORIDAZINE (ORAL)	0.1%	OFF	No-Gen			
ZIPRASIDONE CAPSULE (ORAL)	6.3%	ON	Yes-Gen			
RISPERIDONE SOLUTION (ORAL)	0.6%	ON	Yes-Gen			
FANAPT TITRATION PACK (ORAL)	0.0%	OFF	No			
TRIFLUOPERAZINE (ORAL)	0.2%	ON	Yes-Gen			
AMITRIPTYLINE / PERPHENAZINE (ORAL)	0.1%	ON	Yes-Gen			
THIOTHIXENE (ORAL)	0.2%	ON	Yes-Gen			
LATUDA (ORAL)	4.7%	ON	Yes			
CLOZAPINE (ORAL)	2.5%	ON	Yes-Gen			
FANAPT TABLET (ORAL)	0.2%	OFF	No			
PERPHENAZINE (ORAL)	0.3%	ON	Yes-Gen			
ADASUVE (INHALATION)	0.0%	OFF	No			
SEROQUEL XR (ORAL)	1.6%	OFF	No			
OLANZAPINE ODT (ORAL)	0.3%	OFF	No-Gen			
SAPHRIS (SUBLINGUAL)	0.5%	OFF	No			
RISPERIDONE ODT (ORAL)	0.5%	ON	Yes-Gen			
ABILIFY TABLET (ORAL)	13.8%	OFF	No			
ABILIFY SOLUTION (ORAL)	0.1%	OFF	No			
FLUPHENAZINE ELIXIR/SOLN (ORAL)	0.0%	ON	Yes-Gen			
SYMBYAX (ORAL)	0.0%	OFF	No			
ABILIFY DISCMELT (ORAL)	0.0%	OFF	No			
INVEGA (ORAL)	1.2%	OFF	No			
OLANZAPINE/FLUOXETINE (ORAL)	0.0%	OFF	No-Gen			
CLOZAPINE ODT (AG) (ORAL)	0.1%	OFF	No-Gen			
CHLORPROMAZINE (ORAL)	0.5%	ON	Yes-Gen			
VERSACLOZ (ORAL)	0.0%	OFF	No			
REXULTI (ORAL)	0.0%	NR	No			
ARIPIPRAZOLE TABLET (ORAL)	0.0%	NR	No-Gen			
HALOPERIDOL DECANOATE (INJECTION)	1.0%	NR	Yes-Gen			
FLUPHENAZINE DECANOATE (INJECTION)	0.3%	NR	Yes-Gen			
HALDOL DECANOATE (INTRAMUSC)	0.0%	NR	Yes			
RISPERDAL CONSTA (INTRAMUSC.)	1.3%	NR	Yes			
ZYPREXA RELPREVV (INTRAMUSC)	0.0%	NR	Yes			
INVEGA SUSTENNA (INTRAMUSC)	1.4%	NR	Yes			
ABILIFY MAINTENA (INTRAMUSC.)	0.5%	NR	Yes			
INVEGA TRINZA (INTRAMUSC)	0.0%	NR	Yes			

- Discussion: Rachel Currans-Henry stated that generic aripiprazole pricing is expected to decrease in the near future. Rick Pope indicated that he anticipated the cost to decrease around January 1, 2016 to where it would then be favorable to the state to make the change. Catherine Decker questioned how the pharmacies are notified and how much lead time is given when these types of changes happen in between meetings. Kimberly Smithers stated that updates are published, the PDL is posted on the portal and PSW is notified to reach out to their members. There was group discussion regarding whether or not this recommendation would be necessary, as the secretary has the authority to make the decision but Kevin Moore stated the secretary prefers to have the support of the committee. Lynn clarified the situation by explaining when a drug is non-preferred such as Abilify and a generic equivalent is available and cost effective, staff generally makes the committee aware of these situations to get the committee's recommendation for a status change. It was discussed if the committee agreed that the generic aripiprazole should become preferred when cost effective. Kevin Moore restated that the current motion was to accept recommendations along with allowing the state to change aripiprazole from non-preferred to preferred status when the price is cost effective to the State.
- Pat Towers made a motion to accept recommendations and supports state staff changing aripiprazole to preferred when cost effective. She requested that staff report back to the committee at the next meeting if the status change occurs.
  - Second-William Raduege
  - 7 members were in favor of the motion. Roseanne Barber opposed the motion.
  - Motion passes.

SEDATIVE HYPNOTICS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
SILENOR (ORAL)	0.1%	OFF	No			
ZOLPIDEM (ORAL)	74.9%	ON	Yes-Gen			
TEMAZEPAM (ORAL)	13.2%	ON	Yes-Gen			
FLURAZEPAM (ORAL)	0.1%	OFF	No-Gen			
ZALEPLON (ORAL)	2.1%	ON	Yes-Gen			
ESZOPICLONE (ORAL)	2.5%	OFF	No-Gen			
ESTAZOLAM (ORAL)	0.4%	ON	Yes-Gen			
TRIAZOLAM (ORAL)	0.9%	ON	Yes-Gen			
INTERMEZZO (SUBLINGUAL)	0.0%	OFF	No			
ROZEREM (ORAL)	2.3%	ON	Yes			
ZOLPIDEM ER (ORAL)	3.0%	OFF	No-Gen			
EDLUAR (SUBLINGUAL)	0.0%	OFF	No			
TEMAZEPAM 7.5 MG (ORAL)	0.1%	OFF	No-Gen			
BELSOMRA (ORAL)	0.5%	NR	No			
TEMAZEPAM 22.5 MG (ORAL)	0.0%	OFF	No-Gen			

- Discussion: None

- William Raduege made a motion to accept staff recommendations as presented.
  - Second-Roseanne Barber
  - All members were in favor of the motion.
  - Motion passes.

STIMULANTS AND RELATED AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
METADATE CD (ORAL)	2.1%	ON	Yes			
DEXEDRINE SPANSULE (ORAL)	0.1%	ON	No			
DEXMETHYLPHENIDATE (AG) (ORAL)	0.1%	ON	Yes-Gen			
METHYLIN CHEWABLE TABLETS (ORAL)	0.0%	ON	Yes			
GUANFACINE ER (ORAL)	0.2%	NR	Yes-Gen			
METHYLIN SOLUTION (ORAL)	0.0%	OFF	No			
DEXMETHYLPHENIDATE XR (AG) (ORAL)	0.0%	OFF	No-Gen			
FOCALIN (ORAL)	0.0%	ON	Yes			
FOCALIN XR (ORAL)	4.0%	ON	Yes			
DEXMETHYLPHENIDATE (ORAL)	0.9%	ON	Yes-Gen			
METHYLPHENIDATE (ORAL)	6.3%	ON	Yes-Gen			
KAPVAY (ORAL)	0.1%	OFF	No			
AMPHETAMINE SALT COMBO (ORAL)	20.2%	ON	No-Gen			
RITALIN LA (ORAL)	0.1%	OFF	No			
STRATTERA (ORAL)	3.6%	ON	Yes			
VYVANSE (ORAL)	15.7%	ON	Yes			
METHYLPHENIDATE ER (CONCERTA) (AG) (ORAL)	8.6%	ON	Yes-Gen			
ADDERALL XR (ORAL)	25.5%	ON	No			
RITALIN LA 10 MG CAPSULE (ORAL)	0.0%	OFF	No			
DESOXYN (ORAL)	0.0%	OFF	No			
QUILLIVANT XR (ORAL)	0.5%	ON	Yes			
DAYTRANA (TRANSDERMAL)	0.6%	ON	Yes			
DEXTROAMPHETAMINE TABLET (ORAL)	0.7%	ON	No-Gen			
DEXEDRINE TABLET (ORAL)	0.0%	NR	No-Gen			
ZENZEDI (ORAL)	0.0%	OFF	No-Gen			
NUVIGIL (ORAL)	0.1%	OFF	No			
METHYLPHENIDATE CD (AG) (ORAL)	0.0%	OFF	No-Gen			
APTENSIO XR (ORAL)	0.0%	NR	No			
METHYLPHENIDATE ER (GEN RITALIN LA) (ORAL)	0.1%	OFF	No-Gen			
AMPHETAMINE SALT COMBO ER (ORAL)	0.0%	OFF	No-Gen			
DEXMETHYLPHENIDATE XR (ORAL)	0.0%	OFF	No-Gen			
AMPHETAMINE SALT COMBO ER (AG) (ORAL)	0.0%	OFF	No-Gen			
METHYLPHENIDATE CHEWABLE TABLETS (ORAL)	0.0%	NR	No-Gen			
PROCENTRA (ORAL)	0.0%	ON	No-Gen			
CLONIDINE ER (ORAL)	0.4%	OFF	No-Gen			
EVEKEO (ORAL)	0.0%	NR	No-Gen			
METHYLPHENIDATE ER (CONCERTA) (ORAL)	2.8%	ON	Yes-Gen			
METHYLPHENIDATE ER (ORAL)	1.0%	ON	Yes-Gen			
METHYLPHENIDATE CD (ORAL)	0.0%	OFF	No-Gen			
DEXTROAMPHETAMINE CAPSULE ER (ORAL)	0.9%	ON	No-Gen			
METHYLPHENIDATE SOLUTION (ORAL)	0.0%	OFF	No-Gen			
METHYLPHENIDATE SOLUTION (AG) (ORAL)	0.0%	OFF	No-Gen			
DEXTROAMPHETAMINE SOLUTION (ORAL)	0.0%	OFF	No-Gen			
METHAMPHETAMINE (ORAL)	0.0%	OFF	No-Gen			
MODAFINIL (ORAL)	0.1%	OFF	No-Gen			

- Discussion: Rachel Currans-Henry stated that the intent of the recommendations is to better control the use of stimulants. Adderall is one of our costliest and most utilized drugs. We need to better manage this drug and other stimulants with regards to abuse. For new starts only, we want to require members to use Vyvanse and one additional preferred stimulant prior to being able to obtain approval for a non-preferred amphetamine product. Although Vyvanse is an amphetamine product, it has a lower misuse potential because it is considered a pro-drug and is not an active form of amphetamine. Kevin Izard requested clarification of the step therapy for amphetamines and Kimberly Smithers explained that Vyvanse and one additional preferred stimulant would be required before amphetamines would be considered for approval. Catherine Decker asked if any maximum dosage limits would apply after the step therapy requirement is met. Rachel Currans-Henry stated there are currently no limits but DUR activities are working to change prescribing behavior in multiple ways to manage misuse of amphetamine products and address overdosing concerns.

The committee discussed public testimony from a physician who expressed concern that the allowable diagnosis codes for drugs in this class, do not allow for treatment of individuals diagnosed with idiopathic hypersomnia (idiopathic hypersomnia is a sleep disorder without a clear cause, in which you are excessively sleepy during the day).

The Committee was informed that staff has followed this issue and at this point, the data and literature provided is not strong enough for us to allow coverage for the off-label use of idiopathic hypersomnia. The Committee discussed this extensively. Some committee members felt strongly that consideration should be given to this issue since the testimony was provided by a physician. Other committee members felt we should proceed with caution before expanding access to stimulants. One committee member felt access could be allowed since they were only requesting consideration for methylphenidate. It was clarified that the testimony given was not for a specific drug, but to allow idiopathic hypersomnia as a covered diagnosis for any medication used for narcolepsy.

- Kevin Izard made a motion to accept staff recommendations as presented and requested that the state investigate adding idiopathic hypersomnia as a covered diagnosis and report back to the committee.
  - Second-John Fangman
  - All members were in favor of the motion.
  - Motion passes.



METHOTREXATE						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
METHOTREXATE VIAL (INJECTION)	5.3%	NR	Yes-Gen			
METHOTREXATE PF VIAL (INJECTION)	2.3%	NR	Yes-Gen			
METHOTREXATE TABLET (ORAL)	90.1%	NR	Yes-Gen			
TREXALL TABLET (ORAL)	0.8%	NR	No-Gen			
RHEUMATREX TABLET DOSE PACK (ORAL)	0.0%	NR	No			
RASUVO AUTO INJECTOR (SUBCUT.)	0.4%	NR	No			
OTREXUP AUTO INJECTOR (SUBCUT.)	1.1%	NR	No			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
  - Second-John Fangman
  - All members were in favor of the motion.
  - Motion passes.